A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.
This study focuses on Acute Ischemic Stroke, a condition that occurs when a blood vessel supplying the brain becomes blocked, preventing oxygen from reaching brain cells. The research aims to evaluate the effectiveness and safety of tenecteplase compared to the current standard medical treatments. This study is specifically looking at individuals who were last seen well more than 4.5 hours before receiving treatment, including cases known as wake-up stroke, where the exact time the symptoms started is unknown. This group includes people who show evidence through imaging, such as a computed tomography scan, that there is still salvageable brain tissue that can be saved if blood flow is restored.
During the trial, participants will receive either tenecteplase or the standard of care via an intravenous bolus, which is a method of delivering medication directly into a vein in a single quick dose. The study will monitor how well patients recover and function over a period of time, specifically looking at their ability to perform daily activities 90 days after the event. The researchers will also observe for any potential side effects, such as symptomatic intracranial hemorrhage, which is a type of bleeding inside the brain that can occur following treatment.
Who Can Join the Study?
You must be a man or a woman who is at least 18 years old, or the legal age of adulthood in your country.
You must provide a signed and dated consent form, which is a written document where you agree to take part in the study.
You must have had an acute ischaemic stroke, which is a sudden blockage of blood flow to part of the brain that causes brain cells to die.
The stroke must be a wake-up stroke, which means the stroke happened while you were sleeping and was only discovered when you woke up.
The stroke must affect the supratentorial circulation, which refers to the upper part of the brain.
The time since you were last known to be healthy must be more than 4.5 hours before you are assigned to a treatment group.
Before the stroke, you must have had a modified Rankin Scale (mRS) score of 1 or less, which means you were able to function well and perform daily activities without significant help.
You must meet specific requirements based on imaging, which means doctors must see certain results on your MRI (a detailed scan using magnets) or CT scan (a scan using X-rays) to ensure you can participate.
Who Cannot Join the Study?
You cannot participate if you plan to undergo mechanical thrombectomy, which is a surgical procedure to remove a blood clot, at the same hospital where you start the study.
You are excluded if you have a history of damage to the central nervous system, which is the part of the body consisting of the brain and spinal cord, such as a neoplasm (a tumor or abnormal growth), an aneurysm (a weak or bulging spot in an artery wall), or malformations (abnormal developments) of the blood vessels.
You cannot join if you have had previous surgery on your brain or spine.
You are excluded if you have other medical conditions or health issues that increase your risk of bleeding outside of the brain.
You cannot participate if you have any medical reasons why you are not allowed to take tenecteplase, which is a medicine used to dissolve blood clots.
You are excluded if you have a blockage in the internal carotid artery, which is one of the main large blood vessels in the neck that supplies blood to the brain.
You cannot join if you are considered a high-risk patient, meaning you have a greater chance of experiencing a hemorrhage, which is bleeding inside the body, as a result of the treatment.
You are excluded if any scans of your brain, such as a non-contrast CT scan (an X-ray of the brain without special dye) or an MRI (a detailed image using magnets), show any signs of bleeding in the brain.
You cannot participate if you are unable to undergo brain imaging that uses contrast, which is a special dye used to make blood vessels and tissues easier to see on scans.
You are excluded if your stroke is considered severe based on a clinical scale called the NIHSS, which is a tool used by doctors to measure the seriousness of stroke symptoms.
You cannot join if your stroke symptoms are minor and do not cause significant disability, or if your symptoms are improving very quickly.
You are excluded if your brain scans or physical symptoms do not show an acute ischemic stroke, which is a stroke caused by a sudden blockage of blood flow to the brain, or if they suggest the stroke happened more than 72 hours ago.
You cannot participate if you are already scheduled to receive intravenous thrombolysis, which is the standard medical treatment of using medicine through a vein to break up a clot.
Tenecteplase is a medication given through a vein that is used to help dissolve blood clots in the brain to help restore blood flow during an acute ischemic stroke.
Acute Ischemic Stroke – This condition occurs when a blood vessel supplying blood to the brain becomes blocked by a clot. The lack of blood flow prevents oxygen and nutrients from reaching brain cells. As a result, the affected brain cells begin to suffer damage and may die. The symptoms can appear suddenly depending on which part of the brain is affected. The progression of the damage is often linked to how quickly the blood flow is restored.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Bulgaria 
Greece 
Hungary 
Norway 
Romania 
Spain 
